Tibsovo (ivosidenib tablets) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease
• Patient has relapsed or refractory disease

Approval duration

1 year